基因泰克重组人胰岛素技术开发历程及启示

Process and Revelation of Genentech's Recombinant Human Insulin Technology Development

20世纪70年代,随着基因工程技术的发展,重组人胰岛素成为生物技术开发的热点之一。美国基因泰克公司的技术人员首先成功完成重组人胰岛素技术开发的成功。本文利用相关的历史文献和口述资料,详细地展现了基因泰克公司开发重组人胰岛素技术的历程,总结出基因泰克公司利用风险投资的资金,依靠技术外援和自己的技术团队,借助已有的实验室和设备,选择并执行适合自身条件的技术开发路径,探索出基因工程技术开发的新模式,为生物科技公司的发展提供了一种新思路。

In 1970s, with the development of genetic engineering technology, recombinant human insulin had been one of the hotspots of biotechnological development. Technicians of American Genentech Company have firstly achieved the success of recombinant human insulin technology development. This paper uses the relevant historical documents and oral history materials to thoroughly present the process of Genentech＇s recombinant human insulin technology development, and concludes that Genentech company explored a new model of genetic engineering technology development by raising the venture capital to fund technical aid, relying on existing laboratories and facilities and setting up own technical team to choose and carry out the suitable technical pathway, and provided a new thought for the development of biotechnology companies.